Acadia Pharma (ACAD) Tops Q3 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 17c

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 8, 2021 4:05 PM EST

- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20

- FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.

Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial teams ability to drive sales of NUPLAZID in a challenging environment, said Steve Davis, Chief Executive Officer. As we... More